Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Robert Spanheimer"'
Publikováno v:
Diabetes, Obesity and Metabolism. 16:63-74
Aims The PROactive study investigated pioglitazone for secondary prevention of macrovascular events in type 2 diabetes mellitus. Pioglitazone showed a 10% (non-significant) relative risk (RR) reduction for the primary composite endpoint and a signifi
Autor:
Bernard Charbonnel, John A. Dormandy, Robert Spanheimer, Markku Laakso, Eleuterio Ferrannini, Erland Erdmann, Ralph A. DeFronzo, D. J. Betteridge, Robert G. Wilcox
Publikováno v:
Diabetes, Obesity and Metabolism. 13:759-764
Aim: In PROactive, pioglitazone reduced the incidence of death, myocardial infarction and stroke, and significantly improved HbA1c, systolic blood pressure (SBP), triglycerides and high-density lipoprotein (HDL)-cholesterol relative to placebo. As th
Publikováno v:
J Clin Hypertens (Greenwich)
J Clin Hypertens (Greenwich). Type 2 diabetes mellitus (T2DM) treatment should not increase cardiovascular (CV) risk and at best could provide benefit beyond lowering glucose. Pioglitazone has demonstrated a favorable CV profile relative to other ora
Publikováno v:
Current Medical Research and Opinion. 25:2915-2923
Studies have shown that many patients with type 2 diabetes do not achieve optimal glycemic control, and progression of diabetes over time requires more than one pharmacotherapy to achieve glycemic goal.To examine the efficacy and safety of the fixed-
Autor:
Eberhard Standl, Massimo Massi-Benedetti, Bernard Charbonnel, John Yates, Robert Spanheimer, John A. Dormandy, Allan M. Skene, Robert G. Wilcox, Erland Erdmann, Meng Tan
Publikováno v:
Diabetes Care. 30:2773-2778
OBJECTIVE— PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) enrolled patients with type 2 diabetes and preexisting cardiovascular disease. These patients were at high risk for heart failure, so any therapeutic benefit cou
Autor:
Michael R. McClung, Henry G. Bone, Marsha Raanan, Alfonso Perez, Robert Lindsay, Robert Spanheimer
Context: Meta-analyses of clinical studies have suggested an increased incidence of peripheral fractures in postmenopausal women with type 2 diabetes mellitus taking pioglitazone. The mechanism behind this apparent increase is unknown. Objective: The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98abcada79d4d7363d0c9364c7649af6
https://acuresearchbank.acu.edu.au/item/87zz7/effects-of-pioglitazone-on-bone-in-postmenopausal-women-with-impaired-fasting-glucose-or-impaired-glucose-tolerance-a-randomized-double-blind-placebo-controlled-study
https://acuresearchbank.acu.edu.au/item/87zz7/effects-of-pioglitazone-on-bone-in-postmenopausal-women-with-impaired-fasting-glucose-or-impaired-glucose-tolerance-a-randomized-double-blind-placebo-controlled-study
Publikováno v:
Journal of diabetes. 2(3)
Background: Patients with Type 2 diabetes mellitus (T2DM) are often treated with multiple glucose-lowering and cardiovascular agents. The concomitant use of nitrates, renin–angiotensin system (RAS) blockers, or insulin has been linked to a potentia
Publikováno v:
The American journal of cardiology. 104(2)
Studies have shown that pioglitazone treatment in patients with type 2 diabetes mellitus can improve parameters of diabetic dyslipidemia. The aim of this study was to examine the effect of pioglitazone on triglycerides, high-density lipoprotein chole
Autor:
Erland, Erdmann, Bernard, Charbonnel, Robert G, Wilcox, Allan M, Skene, Massimo, Massi-Benedetti, John, Yates, Meng, Tan, Robert, Spanheimer, Eberhard, Standl, John A, Dormandy, T D M, Williams
Publikováno v:
Diabetes care. 30(11)
PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) enrolled patients with type 2 diabetes and preexisting cardiovascular disease. These patients were at high risk for heart failure, so any therapeutic benefit could potentiall
Autor:
Alfonso Perez, Paulos Berhanu, Robert Spanheimer, Mehmood Khan, Seleshi Demissie, Mark S Kipnes, Penny R. Fleck, Stuart Kupfer
Publikováno v:
Diabetesvascular disease research. 3(1)
4The aim of this study was to evaluate changes in lipid profiles in patients with type 2 diabetes after treatment conversion from rosiglitazone to pioglitazone while maintaining stable statin and other lipid-altering therapies. A total of 305 patient